BridgeBio Pharma vs Corcept Therapeutics
BBIO and CORT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BBIO and CORT compare
BridgeBio Pharma is the larger company, worth 1.7 times as much as Corcept Therapeutics ($14.7B against $8.8B).
BridgeBio Pharma grew revenue faster over the last twelve months (167% versus 16.0% for Corcept Therapeutics).
Corcept Therapeutics scores higher on the StockData Score (11 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BBIO | CORT |
|---|---|---|
| Size and price | ||
| Market cap | $14.7B | $8.8B |
| Share price | $74.95 | $81.12 |
| Change, 1 year | 12.5% | 12.6% |
| Change, 5 years | 40.3% | 292% |
| Beta (5Y) | 1.13 | 0.55 |
| Employees | 834 | 730 |
| StockData Score | ||
| Total score | 3 | 11 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 193× |
| P/S | 15.5× | 10.6× (better) |
| P/B | – | 12.4× |
| EV/EBITDA | – | 1047× |
| P/FCF | – | 82.0× |
| FCF yield | −2.5% | 1.2% (better) |
| Fair value | – | $15.98 |
| Margin of safety | – | −408% |
| Growth | ||
| Revenue growth (TTM) | 167% (better) | 16.0% |
| Revenue growth, 5Y average | 127% (better) | 16.6% |
| Net income growth (TTM) | – | −58.7% |
| EPS growth (TTM) | – | −62.5% |
| EPS growth, 5Y average | – | −0.72% |
| Profitability | ||
| Gross margin | 94.3% | 98.3% (better) |
| Operating margin | −38.5% | 0.77% (better) |
| Net margin | – | 6.6% |
| FCF margin | −39.1% | 12.9% (better) |
| Return on equity | – | 8.2% |
| Return on invested capital | – | 1.9% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −7.1× | – |
| Current ratio | 2.09 | 2.86 (better) |
| Altman Z-score | 0.06 | 31.14 (better) |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Buyback yield | 1.7% (better) | 0.48% |
| Shareholder yield | 1.7% (better) | 0.48% |
| Ownership | ||
| Held by institutions | 99.1% | 76.2% |
| Held by insiders | 35.5% | 14.4% |
| Insider net buying, 12 months | −$105M | −$92.1M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 15.6% | 9.2% |
Go deeper
- BBIO stock overview
- BBIO income statement
- BBIO valuation and score
- CORT stock overview
- CORT income statement
- CORT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.